SymbolCMPS
NameCOMPASS PATHWAYS PLC
SectorHEALTH CARE
RegionEurope
IndustryBiotechnology: Pharmaceutical Preparations
Address33 BROADWICK STREET,3RD FLOOR, LONDON, W1F 0DQ, United Kingdom
Telephone1-716-676-6461
Fax
Email
Websitehttps://compasspathways.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001816590
Description

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Additional info from NASDAQ:
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

2026-04-24 14:37

Compass Pathways - Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioners National Priority Voucher

Read more
2026-04-24 14:37

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioners National Priority Voucher

Read more
2026-04-21 10:30

Compass Pathways - Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Read more
2026-04-21 10:30

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Read more
2026-04-20 10:30

Compass Pathways - Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Read more
2026-04-20 10:30

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Read more
2026-04-18 20:12

Compass Pathways - Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Read more
2026-04-18 20:12

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Read more
2026-04-15 17:36

New Form ARS - COMPASS Pathways plc <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-157141 <b>Size:</b> 9 MB

Read more
2026-04-15 17:33

New Form DEF 14A - COMPASS Pathways plc <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-157123 <b>Size:</b> 3 MB

Read more